Vericel lifts 2026 guidance on 22% revenue growth and launches $200M buyback
VCEL sits 68% above its 52-week low of $28.95.
Summary
Vericel posted Q2 revenue of $77.5M (+22% YoY), raised full-year guidance, and announced its first-ever $200M share repurchase program — a strong signal of financial health and shareholder focus.
Key Events · Earnings and Guidance · VCEL
-
Q2 Revenue Up 22% to $77.5M
Driven by 23% growth in MACI and 22% growth in Burn Care, total revenue rose 22% year-over-year. Net income reached $2.2 million, or $0.04 per diluted share, swinging from a net loss a year ago.
-
Full-Year Guidance Raised
Management lifted 2026 revenue guidance to $330–$340 million (from $326–$336 million), with MACI expected at $284–$290 million and Burn Care at $46–$50 million. Profitability guidance was reaffirmed.
-
$200M Share Repurchase Authorized
The board approved a $200 million buyback program — the company's first. With $227 million in cash and no debt, Vericel can fund repurchases while continuing to invest in growth.
-
Strong Cash Generation
Free cash flow was $14.3 million in Q2 and $29.4 million for the first half, reflecting improving profitability and disciplined capital spending.
Analysis · VCEL · Life Sciences
A standout second quarter saw revenue climb 22% to $77.5 million, flipping the bottom line to a net profit. Bolstered by sustained demand for MACI and burn care products, management raised full-year revenue guidance to $330–$340 million. In a first for the company, the board authorized a $200 million share repurchase program — a move that, backed by $227 million in cash and zero debt, underscores a clear commitment to returning capital to shareholders. The buyback represents roughly 8% of the current market cap and could provide a meaningful floor for the stock, especially as it trades near all-time highs.
At the time of this filing, VCEL was trading at $48.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $28.95 to $48.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.